Array ( [0] => WP_Term Object ( [term_id] => 22 [name] => Other [slug] => other-program [term_group] => 0 [term_taxonomy_id] => 22 [taxonomy] => category [description] => [parent] => 9 [count] => 2 [filter] => raw [cat_ID] => 22 [category_count] => 2 [category_description] => [cat_name] => Other [category_nicename] => other-program [category_parent] => 9 ) [1] => WP_Term Object ( [term_id] => 16 [name] => UpRi (XMT-1536) [slug] => xmt-1536 [term_group] => 0 [term_taxonomy_id] => 16 [taxonomy] => category [description] => [parent] => 9 [count] => 26 [filter] => raw [cat_ID] => 16 [category_count] => 26 [category_description] => [cat_name] => UpRi (XMT-1536) [category_nicename] => xmt-1536 [category_parent] => 9 ) [2] => WP_Term Object ( [term_id] => 15 [name] => XMT-1522 [slug] => xmt-1522 [term_group] => 0 [term_taxonomy_id] => 15 [taxonomy] => category [description] => [parent] => 9 [count] => 4 [filter] => raw [cat_ID] => 15 [category_count] => 4 [category_description] => [cat_name] => XMT-1522 [category_nicename] => xmt-1522 [category_parent] => 9 ) [3] => WP_Term Object ( [term_id] => 17 [name] => XMT-1592 [slug] => xmt-1592 [term_group] => 0 [term_taxonomy_id] => 17 [taxonomy] => category [description] => [parent] => 9 [count] => 1 [filter] => raw [cat_ID] => 17 [category_count] => 1 [category_description] => [cat_name] => XMT-1592 [category_nicename] => xmt-1592 [category_parent] => 9 ) [4] => WP_Term Object ( [term_id] => 18 [name] => XMT-1660 [slug] => xmt-1660 [term_group] => 0 [term_taxonomy_id] => 18 [taxonomy] => category [description] => [parent] => 9 [count] => 3 [filter] => raw [cat_ID] => 18 [category_count] => 3 [category_description] => [cat_name] => XMT-1660 [category_nicename] => xmt-1660 [category_parent] => 9 ) [5] => WP_Term Object ( [term_id] => 19 [name] => XMT-2056 [slug] => xmt-2056 [term_group] => 0 [term_taxonomy_id] => 19 [taxonomy] => category [description] => [parent] => 9 [count] => 7 [filter] => raw [cat_ID] => 19 [category_count] => 7 [category_description] => [cat_name] => XMT-2056 [category_nicename] => xmt-2056 [category_parent] => 9 ) )

Array ( [99] => WP_Term Object ( [term_id] => 19 [name] => XMT-2056 [slug] => xmt-2056 [term_group] => 0 [term_taxonomy_id] => 19 [taxonomy] => category [description] => [parent] => 9 [count] => 7 [filter] => raw [cat_ID] => 19 [category_count] => 7 [category_description] => [cat_name] => XMT-2056 [category_nicename] => xmt-2056 [category_parent] => 9 ) [28] => WP_Term Object ( [term_id] => 18 [name] => XMT-1660 [slug] => xmt-1660 [term_group] => 0 [term_taxonomy_id] => 18 [taxonomy] => category [description] => [parent] => 9 [count] => 3 [filter] => raw [cat_ID] => 18 [category_count] => 3 [category_description] => [cat_name] => XMT-1660 [category_nicename] => xmt-1660 [category_parent] => 9 ) [25] => WP_Term Object ( [term_id] => 17 [name] => XMT-1592 [slug] => xmt-1592 [term_group] => 0 [term_taxonomy_id] => 17 [taxonomy] => category [description] => [parent] => 9 [count] => 1 [filter] => raw [cat_ID] => 17 [category_count] => 1 [category_description] => [cat_name] => XMT-1592 [category_nicename] => xmt-1592 [category_parent] => 9 ) [20] => WP_Term Object ( [term_id] => 16 [name] => UpRi (XMT-1536) [slug] => xmt-1536 [term_group] => 0 [term_taxonomy_id] => 16 [taxonomy] => category [description] => [parent] => 9 [count] => 26 [filter] => raw [cat_ID] => 16 [category_count] => 26 [category_description] => [cat_name] => UpRi (XMT-1536) [category_nicename] => xmt-1536 [category_parent] => 9 ) [10] => WP_Term Object ( [term_id] => 15 [name] => XMT-1522 [slug] => xmt-1522 [term_group] => 0 [term_taxonomy_id] => 15 [taxonomy] => category [description] => [parent] => 9 [count] => 4 [filter] => raw [cat_ID] => 15 [category_count] => 4 [category_description] => [cat_name] => XMT-1522 [category_nicename] => xmt-1522 [category_parent] => 9 ) [] => WP_Term Object ( [term_id] => 22 [name] => Other [slug] => other-program [term_group] => 0 [term_taxonomy_id] => 22 [taxonomy] => category [description] => [parent] => 9 [count] => 2 [filter] => raw [cat_ID] => 22 [category_count] => 2 [category_description] => [cat_name] => Other [category_nicename] => other-program [category_parent] => 9 ) )

Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients with Platinum Resistance

JAMA Oncology

XMT-2056, a HER2-Directed STING Agonist Antibody-Drug Conjugate, Exhibits ADCC Function that Synergizes with STING Pathway Activation and Contributes to Anti-tumor Responses

American Association for Cancer Research (AACR)

The Evolving Landscape of Antibody-Drug Conjugates in Gynecologic Cancers

Cancer Treatment Reviews

NaPi2b Expression in High-Grade Serous Ovarian Cancer: Results From Combined Data Sets

ESMO Gynaecological Cancers Congress 2023

Targeting NaPi2b in ovarian cancer

Cancer Treatment Reviews

Archival vs Fresh Tumor Samples for Assessing the Gene Expression of NaPi2b and Immune-Related Genes in the Phase 1 Study of Upifitamab Rilsodotin (UpRi) in Platinum-Resistant Ovarian Cancer

34th EORTC-NCI-AACR Symposium

UP-NEXT (GOG-3049/ENGOT-ov71-NSGO-CTU): A Study of Upifitamab Rilsodotin (UpRi), a NaPi2b-directed Antibody-Drug Conjugate (ADC) in Platinum-Sensitive Recurrent Ovarian Cancer

International Gynecologic Cancer Society (IGCS)

UPGRADE: Phase 1 Combination Trial of the NaPi2b-directed Antibody-Drug Conjugate (ADC) Upifitamab Rilsodotin (UpRi; XMT-1536) in Patients With Ovarian Cancer

International Gynecologic Cancer Society (IGCS)

UPLIFT (ENGOT-ov67/GOG-3048): A Pivotal Cohort of the XMT-1536-1 Trial of Upifitamab Rilsodotin (XMT-1536; UpRi), a NaPi2b-directed Antibody-Drug Conjugate (ADC), in Platinum-Resistant Ovarian Cancer

International Gynecologic Cancer Society (IGCS)

Comparison of NaPi2b Expression From Paired Tissue Samples in a Clinical Study of Upifitamab Rilsodotin (UpRi; XMT-1536) Supports a Strategy of Testing in Archival Material

International Gynecologic Cancer Society (IGCS)

Evaluation of NaPi2b Expression in a Well-Annotated Longitudinal Tissue Series of Ovarian Serous Carcinomas

International Gynecologic Cancer Society (IGCS)

XMT-1660: A Phase 1b Trial of a B7-H4–targeting Antibody-Drug Conjugate (ADC) in Endometrial, Ovarian, and Breast Cancers

International Gynecologic Cancer Society (IGCS)

XMT-2056: A Her-2 Targeted Immunosynthen STING agonist antibody drug conjugate

World ADC Summit 2022

XMT-2056: A Her-2 Targeted Immunosynthen STING agonist antibody drug conjugate

Society for Immunotherapy of Cancer (SITC)

XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab

American Association for Cancer Research (AACR)

Anti-tumor effect of XMT-1660, a B7-H4 targeting antibody drug conjugate, in an unselected panel of patient derived xenograft models of breast cancer

American Association for Cancer Research (AACR)

Tumor cell-targeted STING-agonist antibody-drug conjugates achieve potential anti-tumor activity by delivering STING agonist specifically to tumor cells and FcγRI-expressing subset of myeloid cells

American Association for Cancer Research (AACR)

UPLIFT (ENGOT-ov67/GOG-3048): A Pivotal Cohort of Upifitamab Rilsodotin (XMT-1536; UpRi), an NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Platinum-Resistant Ovarian Cancer

SGO 2022 Annual Meeting on Women’s Cancer

Updated Results From the Phase 1b Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer

SGO 2022 Annual Meeting on Women’s Cancer

UPGRADE: Phase 1 Combination Trial of the NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) Upifitamab Rilsodotin (UpRi; XMT-1536) in Patients With Ovarian Cancer

SGO 2022 Annual Meeting on Women’s Cancer

Optimizing the Dose of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC): Updated Analysis of a Phase 1b Expansion Study in Ovarian Cancer

SGO 2022 Annual Meeting on Women’s Cancer

Development of a Novel CDx IHC Assay on the BOND-III to detect NaPi2b in Serous Ovarian Cancer Samples to Identify Patients Eligible for Treatment with Upifitamab Rilsodotin (UpRi)

USCAP 2022 Annual Meeting

STING-Agonist ADCs Targeting Tumor-Associated Antigens Coordinate Immune-Mediated Killing of Antigen-Negative Cancer Cells

Society for Immunotherapy of Cancer (SITC)

XMT-2056: Tumor-targeted Innate Immune Activation via a STING-agonist Antibody Drug Conjugate

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Site Specific Dolasynthen ADCs demonstrate consistent exposure across a wide range of drug-to-antibody ratios

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Interim Data from the Ovarian Cancer Expansion Cohort and Next Steps for UpRi Development Plan

Company Presentation

UpRi (NaPi2b) Diagnostic Development Path

Company Presentation

XMT-1660, a B7-H4-Targeted Dolasynthen Antibody-Drug Conjugate for the Treatment of Breast Cancer

American Association for Cancer Research (AACR)

XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity

American Association for Cancer Research (AACR)

Tumor cell-intrinsic STING pathway activation leads to robust induction of Type III Interferons and contributes to the anti-tumor activity elicited by STING agonism

American Association for Cancer Research (AACR)

Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect

Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research (AACR)

The Dolaflexin-based antibody-drug conjugate XMT-1536 targets the solid tumor lineage antigen SLC34A2/NaPi2b

Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research (AACR)

2021 Virtual Analyst & Investor Day

Company Presentation

Immunosynthen: STING-Agonist ADC Platform

Company Presentation

Tumor cell-intrinsic STING pathway is activated in the presence of cues from immune cells and contributes to the anti-tumor activity of tumor cell-targeted STING agonist antibody-drug conjugates

Society for Immunotherapy of Cancer (SITC)

Safety and Efficacy of XMT-1536 in Ovarian Cancer: A Subgroup Analysis from the Phase 1 Expansion Study of XMT-1536, a NaPi2b Antibody-Drug Conjugate

European Society of Medical Oncology (ESMO)

Tumor Targeting of a STING Agonist by Means of an Antibody-Drug Conjugate Induces Potent Anti-Tumor Immune Responses

Innate Immunity Stimulating Therapies Summit

Systemic Administration of STING Agonist Antibody-Drug Conjugates Elicit Potent Anti-Tumor Immune Responses with Minimal Induction of Circulating Cytokines

American Association for Cancer Research (AACR)

XMT-1592, a Site-Specific Dolasynthen-Based NaPi2b-Targeted Antibody-Drug Conjugate for the Treatment of Ovarian Cancer and Lung Adenocarcinoma

American Association for Cancer Research (AACR)

Phase 1 expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC)

American Society of Clinical Oncology (ASCO)

UPGRADE: Phase 1 Combination Trial of the NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) Upifitamab Rilsodotin (UpRi; XMT-1536) in Patients With Ovarian Cancer

Combination of anti-HER2 ADC XMT-1522 and checkpoint inhibitor pembrolizumab for treatment of NSCLC in preclinical models